Dipeptidyl peptidase‐4 inhibitor lowers PPARγ agonist‐induced body weight gain by affecting food intake, fat mass and beige/brown fat but not fluid retention (1160.9)
Yiling Fu(VA San Diego Healthcare System), Volker Vallon(Unknown), Jan Czogalla(Universität Hamburg), Alexander Kuczkowski(VA San Diego Healthcare System), Miriam Scadeng(University of Auckland), Michael Rose(VA San Diego Healthcare System), Takahiro Masuda(Jichi Medical University), Akiko Eguchi(Mie University), Ariel E. Feldstein(Pediatrics and Genetics), Maria Gerasimova(VA San Diego Healthcare System)
Cited by 1
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5
|Journal of Clinical Investigation|2003|432
Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5
|Journal of Clinical Investigation|2003|404
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Maintenance of Metabolic Homeostasis by Sestrin2 and Sestrin3
|Cell Metabolism|2012|290